New hope for ITP patients: experimental drug aims to boost platelets
NCT ID NCT05885555
First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 21 times
Summary
This study tests an experimental drug called ianalumab in adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. Participants have already tried steroids and another platelet-boosting drug. The goal is to see if ianalumab can safely raise platelet counts to safer levels. About 41 people will take part in this phase 2 trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beth Israel Deaconess Med Center
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Novartis Investigative Site
CABA, C1181ACH, Argentina
-
Novartis Investigative Site
Garran, Australian Capital Territory, 2605, Australia
-
Novartis Investigative Site
Melbourne, Victoria, 3004, Australia
-
Novartis Investigative Site
Wuhan, Hubei, 430022, China
-
Novartis Investigative Site
Beijing, 100730, China
-
Novartis Investigative Site
Jinan, 250012, China
-
Novartis Investigative Site
Toulouse, 31059, France
-
Novartis Investigative Site
Dresden, Saxony, 01307, Germany
-
Novartis Investigative Site
Jena, Thuringia, 07740, Germany
-
Novartis Investigative Site
Giessen, 35392, Germany
-
Novartis Investigative Site
Torino, TO, 10126, Italy
-
Novartis Investigative Site
Johor Bahru, 80100, Malaysia
-
Novartis Investigative Site
Katowice, 40-519, Poland
-
Novartis Investigative Site
Seoul, 06591, South Korea
-
Novartis Investigative Site
Barcelona, Catalonia, 08003, Spain
-
Novartis Investigative Site
Aydin, Efeler, 09100, Turkey (Türkiye)
-
Novartis Investigative Site
Istanbul, Fatih, 34098, Turkey (Türkiye)
-
Novartis Investigative Site
Edirne, Merkez, 22030, Turkey (Türkiye)
-
Novartis Investigative Site
Izmir, 35100, Turkey (Türkiye)
-
Novartis Investigative Site
Kocaeli, 41380, Turkey (Türkiye)
-
Novartis Investigative Site
Glasgow, G31 2ER, United Kingdom
-
Novartis Investigative Site
London, W12 0HS, United Kingdom
Conditions
Explore the condition pages connected to this study.